Aktienanalyse wird geladen …
BDX · NYSE · Medical Devices · USA
179,29 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 21,84 Mrd. | 1,68 Mrd. | 5,82 $ | 288,51 Mio. | 1,4 Mio · 0,5 % | 3,9 Mio · 1,4 % | 45,4 % | 7,7 % | 9,25 $ | 0,89 $ | 4,16 $ |
| 2024 | 20,18 Mrd. | 1,71 Mrd. | 5,86 $ | 291,01 Mio. | 1,4 Mio · 0,5 % | — | 45,2 % | 8,5 % | 10,72 $ | 0,85 $ | 3,80 $ |
| 2023 | 19,37 Mrd. | 1,48 Mrd. | 4,94 $ | 288,39 Mio. | 1,4 Mio · 0,5 % | 0,4 Mio · 0,1 % | 42,2 % | 7,7 % | 7,34 $ | 0,90 $ | 3,64 $ |
| 2022 | 18,87 Mrd. | 1,78 Mrd. | 5,88 $ | 287,36 Mio. | 1,3 Mio · 0,5 % | 6 Mio · 2,1 % | 44,9 % | 9,4 % | 5,21 $ | 0,81 $ | 3,48 $ |
| 2021 | 19,13 Mrd. | 2,09 Mrd. | 6,85 $ | 292,09 Mio. | 1,3 Mio · 0,4 % | — | 45,1 % | 10,9 % | 11,82 $ | 0,78 $ | 3,32 $ |
| 2020 | 16,07 Mrd. | 874 Mio. | 2,71 $ | 282,4 Mio. | 1,3 Mio · 0,5 % | — | 47,1 % | 5,4 % | 9,81 $ | 0,84 $ | 3,16 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|
| Q2 2026 | 4,98 Mrd. | 377 Mio. | 1,37 $ | 275,16 Mio. | 7,6 % | 2,30 $ |
| Q1 2026 | 4,71 Mrd. | -311 Mio. | -1,11 $ | 280,64 Mio. | -6,6 % | 4,29 $ |
| Q4 2025 | 5,25 Mrd. | 382 Mio. | 1,34 $ | 285,85 Mio. | 7,3 % | 1,92 $ |
| Q3 2025 | 7,47 Mrd. | 493 Mio. | 1,71 $ | — | 6,6 % | 5,11 $ |
| Q2 2025 | 4,73 Mrd. | 574 Mio. | 2,00 $ | 287,22 Mio. | 12,2 % | 3,22 $ |
| Q1 2025 | 4,48 Mrd. | 308 Mio. | 1,07 $ | 287,74 Mio. | 6,9 % | -1,11 $ |
| Q4 2024 | 5,17 Mrd. | 303 Mio. | 1,04 $ | 290,39 Mio. | 5,9 % | 2,02 $ |
| Q3 2024 | 5,44 Mrd. | 400 Mio. | 1,39 $ | — | 7,4 % | 3,06 $ |
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices. Its current business centers on medical essentials, connected care, biopharma systems, and interventional products, supporting workflows such as specimen handling, medication delivery, infection prevention, vascular access, and surgical procedures. The company’s portfolio also includes tools and technologies used in drug delivery, patient safety, and clinical research. Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company plays an important role in enabling medical discovery, improving care delivery, and supporting routine operations in healthcare settings worldwide.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest BDX und jede andere Aktie unbegrenzt.